Veramed

Executive Summary

Veramed is a UK-based clinical research organization (CRO) specializing in biometrics for clinical trials, including biostatistics and data management. Founded in 2010 and privately held, the company supports both biologics and small molecules, aiming to set new standards in clinical trial biometrics. Its designation as 'Phase 2' likely reflects involvement in mid-stage clinical trials for client programs, indicating operational maturity but also exposure to drug development risks. Based in London, Veramed benefits from the UK's strong biotech ecosystem. As a service provider, Veramed's growth is driven by new contract wins, client program success, and expanding service offerings. The company faces competition from larger CROs but differentiates through specialized biometrics expertise. While limited public information constrains detailed assessment, Veramed appears well-positioned in a niche segment of the clinical trial market. Near-term catalysts could include major contract announcements, service expansions, or strategic partnerships. Given the lack of disclosed financials or pipeline data, we assign a moderate conviction score.

Upcoming Catalysts (preview)

• Q3 2026Major Contract Win with Top-Tier Pharma60% success
• Q4 2026Service Expansion into New Therapeutic Areas50% success
• Q2 2026Strategic Partnership for Technology or Data Analytics40% success